|
|
|
Summary
of 2004 CPCRA Posters and Presentations
| 6th International Workshop on Adverse Drug Reactions and HIV Lipodystrophy, October 25-28, 2004, Washington, DC |
Ellis KJ, Grund B, Visnegarwala F, Mullin C, Miller CG, Chesson CE, El-Sadr W, Carr A for The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and Body Composition Substudy of Strategies for Management of Anti-Retroviral Therapy Strategies for Management of Anti-Retroviral Therapy (SMART-CPCRA 065C). Abdominal Subcutaneous Adipose Tissue (SAT) and Visceral Adipose Tissue (VAT) Measurements in HIV+ Adults: Influence of Measurement Site. Poster, October 26, 2004.
abstract
| 16th Annual Conference of the Australasian Society for HIV Medicine, September 2-4, 2004, Canberra, Australia |
Drummond F, Neuhaus J, Hoy J on behalf of the SMART Protocol Team and the SMART Study Investigators. The SMART (Strategies for Management of Anti-retroviral Therapy) Study – Adherence to Strategy. Oral.
abstract
| XV International AIDS Conference, July 11-16, 2004, Bangkok, Thailand |
Visnegarwala F, Mullin CM, Giordano TP, Martinez E, Stratton S, Shelburne III S, Gibert C, Carr A, El-Sadr WM. Racial Differences in Prevalence of Self Reported Changes in Body Habitus and their Association with Body Composition Measurements in a Cohort of HIV+ Patients (SMART Study, CPCRA 065). July 14, 2004; Poster; Abstract #WePeB5931.
poster (pdf)
Novak RM, Chen L, MacArthur RD, Baxter
J, Huppler Hullsiek K, Peng G, Xiang Y, Henley C, Schmetter B, Uy
J, van den Berg-Wolf, Kozal M, and the CPCRA 058 Study Team. Prevalence
of Resistance Mutations in a Cohort of Treatment-naïve People
with Chronic HIV infection: CPCRA 058. July 14, 2004; Poster; Abstract
#WePeB5707.
poster (PPT)
Shlay JC, Visnegarwarla F, Bartsch
G, Wang J, Peng G, El-Sadr WM, Gibert C, Kotler D, Grunfeld C, Raghavan
S. Body Composition and Metabolic Changes in Antiretroviral-Naïve
HIV-Infected Patients Randomized to Didanosine and Stavudine (ddI+d4T)
vs Abacavir and Lamivudine (ABC+3TC). July 14, 2004; Poster; Abstract
#ThOrB1360.
abstract | poster
(ppt)
Burman W, Neuhaus J, Rietmeijer C, Douglas J, McCartin C. HIV transmission risk among patients enrolled in a large clinical trial evaluating treatment interruption. July 15, 2004; Poster, Abstract # ThPeD7625.
poster (ppt)
Mannheimer S, Morse M, Matts J, Andrews L, Miller C, Schmetter B, Friedland G, for the CPCRA 062 Study Team. Sustained benefit from a long-term antiretroviral (AR) adherence intervention: Results of a large randomized clinical trial. July 15, 2004; Oral; Abstract #LbOrB15.
abstract | presentation
| XIII International HIV Drug Resistance Workshop, June 8-12, 2004, Costa Adeje, Canary Islands, Spain |
Baxter JD, Leduc RE, DuChene A, Leong H, Furtado MR, Petrauskene OV, and the CPCRA 046 Study Team. Prevalence of HIV-1 GAG Cleaveage Site Mutations in Patients Failing Protease Inhibitors in the GART Study (CPCRA046). Poster.
abstract
Lawrence J, Huppler Hullsiek K, Mayers D, Abrams D, Baxter J, and the CPCRA 064 Study Team. Baseline Resistance and the Predictors of Virologic Response in the CPCRA 064 Study: A Randomized Trial of Structured Treatment Interruption for Patients with Multi-Drug Resistant HIV. Poster.
abstract
| Society for Clinical Trials, 25th Annual Meeting, May 23-26, 2004, New Orleans, LA |
Chen L, Xie Y, Neaton JD. Treatments for HIV infection and implications of non-HIV related deaths on trial design. May 25, 2004; Oral; Session CPSIIIC; Abstract #51.
abstract
Leduc R. A series of unfortunate assays. May 24, 2004; Oral; Session CPSIC, Abstract #16.
abstract
| 11th Conference
on Retroviruses and Opportunistic Infections, February 8-12,
2004, San Francisco, CA |
Mannheimer S, Matts J, Child C, Chesney
M, Telzak E, Wu A, Friedland G. Low-grade symptoms worsen quality
of life (QoL) for HIV-infected individuals in antiretroviral therapy
(ART) clinical trials. Poster.
abstract
Kostman J, Grund B, Leduc R, Baxter
J, Crane L. A randomized trial of 1 or 2 protease inhibitors in
combination with a non-nucleoside reverse transcriptase inhibitor
and background therapy in patients with virologic failure on an
initial protease-inhibitor containing regimen (CPCRA 057). Poster.
abstract
Lawrence J, Huppler Hullsiek K, Abrams
D, Baxter J. Changes in HIV resistance patterns during structured
treatment interruption (STI): CPCRA 064. Poster.
abstract
Drummond F, Mullin C, Poehlman M.
Predictors of low HDL in HIV+ patients: Effect of class of antiretroviral
therapy and traditional risk factors (CPCRA 065). Poster.
abstract
|
|
